Sectoral Asset Management Inc. Sells 198,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Sectoral Asset Management Inc. reduced its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 89.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,872 shares of the company’s stock after selling 198,000 shares during the period. Structure Therapeutics comprises approximately 1.3% of Sectoral Asset Management Inc.’s portfolio, making the stock its 24th biggest holding. Sectoral Asset Management Inc.’s holdings in Structure Therapeutics were worth $1,660,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of GPCR. Principal Financial Group Inc. grew its position in Structure Therapeutics by 63.1% during the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after acquiring an additional 496,726 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Structure Therapeutics during the third quarter valued at approximately $12,923,000. Orbimed Advisors LLC grew its holdings in shares of Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after purchasing an additional 397,272 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in shares of Structure Therapeutics in the third quarter worth approximately $10,440,000. Finally, Casdin Capital LLC grew its holdings in shares of Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after purchasing an additional 330,000 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $39.19 on Monday. The stock has a market cap of $2.78 billion, a P/E ratio of -45.05 and a beta of -1.31. The firm’s fifty day simple moving average is $46.77 and its 200 day simple moving average is $56.81. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on GPCR shares. HC Wainwright cut their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Finally, BMO Capital Markets set a $145.00 target price on shares of Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.